FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells

Ovarian cancer has the highest mortality rate of all gynecological cancers with a high recurrence rate. It is important to understand the nature of recurring cancer cells to terminally eliminate ovarian cancer. The winged helix transcription factor Forkhead box P1 (FOXP1) has been reported to function as either oncogene or tumor-suppressor in various cancers. In the current study, we show that FOXP1 promotes cancer stem cell-like characteristics in ovarian cancer cells. Knockdown of FOXP1 expression in A2780 or SKOV3 ovarian cancer cells decreased spheroid formation, expression of stemness-related genes and epithelial to mesenchymal transition-related genes, cell migration, and resistance to Paclitaxel or Cisplatin treatment, whereas overexpression of FOXP1 in A2780 or SKOV3 ovarian cancer cells increased spheroid formation, expression of stemness-related genes and epithelial to mesenchymal transition-related genes, cell migration, and resistance to Paclitaxel or Cisplatin treatment. In addition, overexpression of FOXP1 increased promoter activity of ABCG2, OCT4, NANOG, and SOX2, among which the increases in ABCG2, OCT4, and SOX2 promoter activity were dependent on the presence of FOXP1-binding site. In xenotransplantation of A2780 ovarian cancer cells into nude mice, knockdown of FOXP1 expression significantly decreased tumor size. These results strongly suggest FOXP1 functions as an oncogene by promoting cancer stem cell-like characteristics in ovarian cancer cells. Targeting FOXP1 may provide a novel therapeutic opportunity for developing a relapse-free treatment for ovarian cancer patients.

[1]  H. Yan,et al.  The identification of the biological characteristics of human ovarian cancer stem cells. , 2014, European review for medical and pharmacological sciences.

[2]  Hongbing Wang,et al.  A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression* , 2003, The Journal of Biological Chemistry.

[3]  Y. Kim,et al.  Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma , 2010, BMC Cancer.

[4]  Wenyan Zhang,et al.  Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients , 2012, Medical Oncology.

[5]  L. Hu,et al.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant , 2010, British Journal of Cancer.

[6]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[7]  A. Harris,et al.  Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression , 2006, Modern Pathology.

[8]  U. Lendahl,et al.  Generating specificity and diversity in the transcriptional response to hypoxia , 2009, Nature Reviews Genetics.

[9]  H. Aburatani,et al.  Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. , 2014, Molecular endocrinology.

[10]  Ming Li,et al.  Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. , 2014, Cancer research.

[11]  A. Rosenwald,et al.  Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. , 2008, Blood.

[12]  E. Lam,et al.  FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis , 2013, Cell Death and Differentiation.

[13]  Zhen-hua Hu,et al.  Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells , 2014, Medical Oncology.

[14]  Y. Hayashizaki,et al.  FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. , 2008, Biochemical and biophysical research communications.

[15]  Huijun Zhu,et al.  High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. , 2012, American journal of clinical pathology.

[16]  M. Zabel,et al.  The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[18]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[19]  C. Gasch,et al.  Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention , 2014, Molecular Cancer.

[20]  Akihiko Osaki,et al.  FOXP1, an Estrogen-Inducible Transcription Factor, Modulates Cell Proliferation in Breast Cancer Cells and 5-Year Recurrence-Free Survival of Patients with Tamoxifen-Treated Breast Cancer , 2011, Hormones & cancer.

[21]  M. Wirth,et al.  Expression of the Forkhead Transcription Factor FOXP1 is Associated with Tumor Grade and Ki67 Expression in Clear Cell Renal Cell Carcinoma , 2011, Cancer investigation.

[22]  G. Enikolopov,et al.  Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.

[23]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[24]  Zhen-hua Hu,et al.  Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis , 2015, Tumor Biology.

[25]  B. Vanderhyden,et al.  Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. , 2014, Reproduction.

[26]  A. Banham,et al.  FOXP1: a potential therapeutic target in cancer , 2007, Expert opinion on therapeutic targets.

[27]  Song He,et al.  Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma , 2012, Journal of Clinical Pathology.

[28]  K. Griffith,et al.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. , 2011, Cancer research.

[29]  C Fidler,et al.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. , 2001, Cancer research.

[30]  Jeffrey L. Wrana,et al.  An Alternative Splicing Switch Regulates Embryonic Stem Cell Pluripotency and Reprogramming , 2011, Cell.

[31]  C. Lengerke,et al.  SOX2 expression associates with stem cell state in human ovarian carcinoma. , 2013, Cancer research.

[32]  R. Arend,et al.  Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? , 2014, World journal of stem cells.

[33]  J.,et al.  The New England Journal of Medicine , 2012 .

[34]  C. Morrison,et al.  Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism , 2014, PloS one.

[35]  Zhen-hua Hu,et al.  The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer. , 2015, Biochimie.